<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369018</url>
  </required_header>
  <id_info>
    <org_study_id>PC CE101/06</org_study_id>
    <nct_id>NCT00369018</nct_id>
  </id_info>
  <brief_title>A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.</brief_title>
  <official_title>Methyl Aminolevulinate (MAL) and Hexaminolevulinate (HAL) Photodynamic Therapy (PDT)of Cervical Intraepithelial Lesions (SIL) - a Double-blind Dose-finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Photocure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Photocure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the best drug (MAL or HAL) dosage for photodynamic therapy of
      cervical precancerous lesions (dysplasia) in women that are referred for conisation
      (surgery).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgery (conisation) of precancerous cervical lesions (dysplasia) increase the risk of
      preterm deliveries in young women. Photodynamic therapy (PDT) is a selective, tissue
      preserving method that may become a good treatment option for these patients.

      This study will explore topical application of methyl aminolevulinate (MAL) and
      hexaminolevulinate (HAL) of the cervix for photodynamic therapy using red light (630 nm).
      Different doses of MAL and HAL will be used with different application time, followed by
      illumination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion eradication</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eradication of lesion and HPV</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Cervical Dysplasia</condition>
  <arm_group>
    <arm_group_label>MAL 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAL 12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HAL 10, 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HAL 10, 12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HAL 40, 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HAL 40, 12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)</intervention_name>
    <description>MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application</description>
    <arm_group_label>MAL 3</arm_group_label>
    <arm_group_label>MAL 12</arm_group_label>
    <arm_group_label>HAL 10, 3</arm_group_label>
    <arm_group_label>HAL 10, 12</arm_group_label>
    <arm_group_label>HAL 40, 3</arm_group_label>
    <arm_group_label>HAL 40, 12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive histology of CIN 1-3

        Exclusion Criteria:

          -  Patients with endocervical lesions

          -  Patients with AGUS

          -  Patients with invasive disease

          -  Patients with porphyria

          -  Patients sensitive to MAL and HAL
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hillemanns, Md PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ullev√•l University Hospital, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2006</study_first_submitted>
  <study_first_submitted_qc>August 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <last_update_submitted>November 26, 2010</last_update_submitted>
  <last_update_submitted_qc>November 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2010</last_update_posted>
  <keyword>photodynamic therapy</keyword>
  <keyword>methyl aminolevulinate</keyword>
  <keyword>hexaminolevulinate</keyword>
  <keyword>dose-finding</keyword>
  <keyword>cervical dysplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

